Shobha Seetharam

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Kenneth J. Pienta, Jean-Pascal Machiels, Dirk Schrijvers et al. · Investigational New Drugs · 2012 · 389 citations

Cnto 888, Medicine, Human Monoclonal Antibody +8

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

Shahneen Sandhu, K. Papadopoulos, Peter C.C. Fong et al. · Cancer Chemotherapy and Pharmacology · 2013 · 254 citations

Tumor Immunology, Cnto 888, Solid Tumors +9

Photoproduct frequency is not the major determinant of UV base substitution hot spots or cold spots in human cells.

Douglas E. Brash, Shobha Seetharam, Kenneth H. Kraemer et al. · Proceedings of the National Academy of Sciences · 1987 · 246 citations · Full text

Ultraviolet Light, Dna Damage, Photobiology +20

Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study

Irene Braña, Antonio Calles, Patricia LoRusso et al. · Targeted Oncology · 2014 · 208 citations

Solid Tumors, Medicine, Immunology +8

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers

François Moisan, E. Brian Francisco, Anamaria Brozović et al. · Molecular Oncology · 2014 · 115 citations · Full text